Biotech · Private company
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Track this companyFree. Adds Dicerna Pharmaceuticals, Inc., a Novo Nordisk company to your Dealase workspace and tells you when its record changes.
Clinical trials133 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- DCR-PHXCPhase 3 · Primary Hyperoxaluria Type 1 (PH1)ClinicalTrials.gov · fetched Nov 12, 2026
- BelcesiranPhase 2 · Alpha 1-Antitrypsin DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- DCR-MYCPhase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- DCR-PHXCPhase 2 · Primary Hyperoxaluria Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- nedosiranPhase 2 · Primary HyperoxaluriaClinicalTrials.gov · fetched Nov 12, 2026
- DCR-AUDPhase 1 · Alcohol Use Disorder (AUD)ClinicalTrials.gov · fetched Nov 12, 2026
- DCR-AUDPhase 1 · Alcohol Use DisorderClinicalTrials.gov · fetched Nov 12, 2026
- DCR-MYCPhase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- DCR-PDL1Phase 1 · Solid Tumors, AdultClinicalTrials.gov · fetched Nov 12, 2026
- DCR-PHXCPhase 1 · Primary Hyperoxaluria Type 3ClinicalTrials.gov · fetched Nov 12, 2026
- DCR-PHXCPhase 1 · Primary HyperoxaluriaClinicalTrials.gov · fetched Nov 12, 2026
- DCR-STAT3Phase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials13
- Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid TumorsPHASE1 · RECRUITING · started May 29, 2024ClinicalTrials.gov NCT06504368 · fetched Nov 12, 2026
- A Study of DCR-STAT3 in Adults With Solid TumorsPHASE1 · COMPLETED · started Aug 14, 2023ClinicalTrials.gov NCT06098651 · fetched Nov 12, 2026
- Phase 1b Study of DCR-AUD in Healthy VolunteersPHASE1 · COMPLETED · started Jan 29, 2023ClinicalTrials.gov NCT05845398 · fetched Nov 12, 2026
- Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal FunctionPHASE2 · COMPLETED · started Feb 22, 2022ClinicalTrials.gov NCT05001269 · fetched Nov 12, 2026
- Study of DCR-AUD in Healthy VolunteersPHASE1 · COMPLETED · started Sep 21, 2021ClinicalTrials.gov NCT05021640 · fetched Nov 12, 2026
- Natural History of Patients With PH3 and a History of Stone EventsCOMPLETED · started Sep 9, 2021ClinicalTrials.gov NCT04542590 · fetched Nov 12, 2026
- Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRDPHASE2 · RECRUITING · started Apr 15, 2021ClinicalTrials.gov NCT04580420 · fetched Nov 12, 2026
- A Study of Belcesiran in Patients With AATLDPHASE2 · TERMINATED · started Feb 12, 2021ClinicalTrials.gov NCT04764448 · fetched Nov 12, 2026
- Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 PatientsPHASE1 · COMPLETED · started Sep 14, 2020ClinicalTrials.gov NCT04555486 · fetched Nov 12, 2026
- Long Term Extension Study in Patients With Primary HyperoxaluriaPHASE3 · ACTIVE_NOT_RECRUITING · started Jul 9, 2019ClinicalTrials.gov NCT04042402 · fetched Nov 12, 2026
- Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary HyperoxaluriaPHASE1 · COMPLETED · started Dec 6, 2017ClinicalTrials.gov NCT03392896 · fetched Nov 12, 2026
- Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular CarcinomaPHASE1_PHASE2 · TERMINATED · started Jan 27, 2015ClinicalTrials.gov NCT02314052 · fetched Nov 12, 2026
- Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or LymphomaPHASE1 · TERMINATED · started Apr 1, 2014ClinicalTrials.gov NCT02110563 · fetched Nov 12, 2026